Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2012 Feb;13(2):207-16. doi: 10.1517/14656566.2012.647767. Epub 2012 Jan 6.

Management options in multiple sclerosis-associated fatigue.

Author information

  • 1University of Florence, Department of Neurology, Viale Morgagni 85, 50134 Florence, Italy. mariapia.amato@unifi.it

Abstract

INTRODUCTION:

Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the CNS. Its characteristic early clinical course includes exacerbations and remissions of neurologic disability. Fatigue is one of the most common symptoms of MS and is associated with a reduced quality of life; it is described as the worst symptom of the disease by 50 - 60% of patients. Yet, due to limitations of available evidence, current therapeutic approaches for treating fatigue are based mainly on preliminary studies and expert consensus.

AREAS COVERED:

This review summarizes current knowledge on the physiopathology, diagnosis and therapeutic options for MS-associated fatigue, including both pharmacological and non-pharmacological strategies.

EXPERT OPINION:

Large, rigorously designed trials can provide more reliable results on the efficacy of interventions for fatigue, their functional impact on everyday activities and patient quality of life. Future research should also address a better understanding of the physiopathologic mechanisms of fatigue and the development and validation of objective assessment tools to be used together with patient self-ratings.

PMID:
22220738
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk